Hot Features
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anae... Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a liquid oral taste-masked reformulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701, a live-attenuated vaccine for the treatment of francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0003 | -2.65486725664 | 0.0113 | 0.0113 | 0.0077 | 47449 | 0.01113912 | CS |
| 4 | -0.00398 | -26.5687583445 | 0.01498 | 0.017 | 0.0077 | 34716 | 0.01016627 | CS |
| 12 | -0.00204 | -15.6441717791 | 0.01304 | 0.0182 | 0.0077 | 41626 | 0.01255945 | CS |
| 26 | -0.0061 | -35.6725146199 | 0.0171 | 0.0182 | 0.0077 | 45426 | 0.01313984 | CS |
| 52 | -0.0012 | -9.83606557377 | 0.0122 | 0.0309 | 0.0077 | 39701 | 0.0151928 | CS |
| 156 | -0.01175 | -51.6483516484 | 0.02275 | 0.0755 | 0.0077 | 139397 | 0.03134443 | CS |
| 260 | -0.5902 | -98.1703260146 | 0.6012 | 0.91 | 0.0077 | 103729 | 0.08006797 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.